Here, we identified that gene sets associated with negative regulation upon oncogenic KRAS signaling as well inflammatory responses were downregulated in KPGEMM and KPCRISPR tumor, while tumor cells upregulated MYC target gene signatures and DNA repair pathways (Figure 3E). The gene discussed is KRAS; the disease is neoplasm.